Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

North America Pharmacogenetic Testing in Psychiatry Depression Market - Industry Trends and Forecast to 2028

Published by Data Bridge Market Research Private Limited Product code 991526
Published Content info 130 Pages
Delivery time: 1-2 business days
Price
Back to Top
North America Pharmacogenetic Testing in Psychiatry Depression Market - Industry Trends and Forecast to 2028
Published: January 1, 2021 Content info: 130 Pages
Description

North America pharmacogenetic testing in psychiatry/depression market is projected to register a CAGR of 9.5% in the forecast period of 2021 to 2028. The new market report contains data for the historic year 2019, the base year of calculation is 2020 and the forecast period is 2021 to 2028

Market Segmentation:

North America Pharmacogenetic Testing in Psychiatry/Depression Market, By Type (Whole Genome Sequencing and Array-Based Tests), Genes (CYP2C19, CYP2C9 and VKORC1, CYP2D6, HLA-B, HTR2A/C, HLA-A, CYP3A4, SLC6A4, MTHFR, COMT and Others), Drug Type (Prescription Drugs, Over-the-Counter Medications, Recreational Drugs and Vitamins/Nutraceuticals), Sample Type (Saliva and Blood), Application (Drug Development and Clinical Practice), End User (Pharmaceutical & Biotechnology Companies, Research Centers and Academic Institutes, Healthcare Providers and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Direct-to-Consumer Services and Mail-Order Pharmacies), Country (U.S., Canada, Mexico) Industry Trends and Forecast to 2028

Some of the major factors contributing to the growth of the North America pharmacogenetic testing in psychiatry/depression market are:

  • Rise in the demand for precision medicine
  • Technological advancements in the field

Market Players:

The key market players for North America pharmacogenetic testing in psychiatry/depression market are listed below:

  • BiogeniQ Inc.
  • GenXys
  • Genomind, Inc.
  • Myriad Genetics, Inc.
  • AltheaDx
  • STADA Arzneimittel AG
  • Sonic Healthcare
  • ONEOME
  • Thermo Fisher Scientific Inc.
  • Millennium Health
  • Coriell Life Sciences
  • Healthspek
  • Color
  • GENELEX
  • OmeCare
  • AB-Biotics, S.A.
  • Luminex Corporation
  • Illumina, Inc.
  • PerkinElmer Inc.
  • HudsonAlpha Health Alliance (a division of HudsonAlpha)
  • Dynamic DNA Laboratories
  • myDNA Life Australia Pty Ltd.
  • R-Biopharm AG
Table of Contents

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 OVERVIEW OF NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET
  • 1.4 LIMITATIONS
  • 1.5 MARKETS COVERED

2 MARKET SEGMENTATION

  • 2.1 MARKETS COVERED
  • 2.2 GEOGRAPHICAL SCOPE
  • 2.3 YEARS CONSIDERED FOR THE STUDY
  • 2.4 CURRENCY AND PRICING
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL
  • 2.6 MULTIVARIATE MODELLING
  • 2.7 TYPE LIFELINE CURVE
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
  • 2.9 DBMR MARKET POSITION GRID
  • 2.10 MARKET APPLICATION COVERAGE GRID
  • 2.11 VENDOR SHARE ANALYSIS
  • 2.12 SECONDARY SOURCES
  • 2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 REGULATIONS: NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET

  • 5.1 UNITED STATES
    • 5.1.1 ROLE OF FDA
    • 5.1.2 ROLE OF CDC AND HCFA
  • 5.2 EUROPEAN UNION
  • 5.3 FRANCE
  • 5.4 AUSTRALIA
  • 5.5 SOUTH KOREA

6 MARKET OVERVIEW

  • 6.1 DRIVERS
    • 6.1.1 RISING NUMBER OF POPULATION SUFFERING FROM DEPRESSIVE DISORDER
    • 6.1.2 INITIATIVES TAKEN BY MANUFACTURERS
    • 6.1.3 GROWING BIOTECHNOLOGY SECTOR ALONG WITH RISING HEALTHCARE EXPENDITURE
    • 6.1.4 INCREASING INTEREST FOR PERSONALIZED AND PRECISION MEDICATION
    • 6.1.5 GROWING MEDICAL TOURISM
  • 6.2 RESTRAINTS
    • 6.2.1 LACK OF STRONG CLINICAL EVIDENCE
    • 6.2.2 HIGH COST
    • 6.2.3 LACK OF REIMBURSEMENT
  • 6.3 OPPORTUNITIES
    • 6.3.1 TECHNOLOGICAL ADVANCEMENTS
    • 6.3.2 EMERGENCE OF NEW PLAYERS
    • 6.3.3 UNTAPPED MARKET
  • 6.4 CHALLENGES
    • 6.4.1 STRINGENT GOVERNMENT REGULATION
    • 6.4.2 SHORTAGE OF SKILLED PERSONNEL

7 COVID-19 IMPACT ON NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET

  • 7.1 IMPACT ON PRICE
  • 7.2 IMPACT ON DEMAND
  • 7.3 IMPACT ON SUPPLY
  • 7.4 KEY INITIATIVES BY MARKET PLAYER DURING COVID 19

7.5 CONCLUSION:

8 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE

  • 8.1 OVERVIEW
  • 8.2 WHOLE GENOME SEQUENCING
  • 8.3 ARRAY-BASED TESTS

9 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES

  • 9.1 OVERVIEW
  • 9.2 CYP2C19
  • 9.3 CYP2C9 AND VKORC1
  • 9.4 CYP2D6
  • 9.5 HLA-B
  • 9.6 HTR2A/C
  • 9.7 HLA-A
  • 9.8 CYP3A4
  • 9.9 SLC6A4
  • 9.10 MTHFR
  • 9.11 COMT
  • 9.12 OTHERS

10 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE

  • 10.1 OVERVIEW
  • 10.2 PRESCRIPTION DRUGS
  • 10.3 OVER-THE-COUNTER MEDICATIONS
  • 10.4 RECREATIONAL DRUGS
  • 10.5 VITAMINS/NUTRACEUTICALS

11 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE

  • 11.1 OVERVIEW
  • 11.2 SALIVA
  • 11.3 BLOOD

12 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION

  • 12.1 OVERVIEW
  • 12.2 DRUG DEVELOPMENT
  • 12.3 CLINICAL PRACTICE

13 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER

  • 13.1 OVERVIEW
  • 13.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
  • 13.3 HEALTHCARE PROVIDERS
  • 13.4 RESEARCH CENTERS AND ACADEMIC INSTITUES
  • 13.5 OTHERS

14 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL

  • 14.1 OVERVIEW
  • 14.2 RETAIL PHARMACIES
  • 14.3 HOSPITAL PHARMACIES
  • 14.4 MAIL-ORDER PHARMACIES
  • 14.5 DIRECT-TO-CUSTOMER SERVICES

15 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GEOGRAPHY

  • 15.1 NORTH AMERICA
    • 15.1.1 U.S.
    • 15.1.2 CANADA
    • 15.1.3 MEXICO

16 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: COMPANY LANDSCAPE

  • 16.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

17 SWOT ANALYSIS

18 COMPANY PROFILE

  • 18.1 MYRIAD GENETICS, INC.
    • 18.1.1 COMPANY SNAPSHOT
    • 18.1.2 REVENUE ANALYSIS
    • 18.1.3 COMPANY SHARE ANALYSIS
    • 18.1.4 PRODUCT PORTFOLIO
    • 18.1.5 RECENT DEVELOPMENTS
  • 18.2 THERMO FISHER SCIENTIFIC INC.
    • 18.2.1 COMPANY SNAPSHOT
    • 18.2.2 REVENUE ANALYSIS
    • 18.2.3 COMPANY SHARE ANALYSIS
    • 18.2.4 PRODUCT PORTFOLIO
    • 18.2.5 RECENT DEVELOPMENT
  • 18.3 STADA ARZNEIMITTEL AG
    • 18.3.1 COMPANY SNAPSHOT
    • 18.3.2 REVENUE ANALYSIS
    • 18.3.3 COMPANY SHARE ANALYSIS
    • 18.3.4 PRODUCT PORTFOLIO
    • 18.3.5 RECENT DEVELOPMENTS
  • 18.4 SONIC HEALTHCARE
    • 18.4.1 COMPANY SNAPSHOT
    • 18.4.2 REVENUE ANALYSIS
    • 18.4.3 COMPANY SHARE ANALYSIS
    • 18.4.4 PRODUCT PORTFOLIO
    • 18.4.5 RECENT DEVELOPMENT
  • 18.5 ILLUMINA, INC.
    • 18.5.1 COMPANY SNAPSHOT
    • 18.5.2 REVENUE ANALYSIS
    • 18.5.3 COMPANY SHARE ANALYSIS
    • 18.5.4 PRODUCT PORTFOLIO
    • 18.5.5 RECENT DEVELOPMENTS
  • 18.6 AB-BIOTICS, S.A.
    • 18.6.1 COMPANY SNAPSHOT
    • 18.6.2 REVENUE ANALYSIS
    • 18.6.3 6.3 PRODUCT PORTFOLIO
    • 18.6.4 RECENT DEVELOPMENTS
  • 18.7 ALTHEADX
    • 18.7.1 COMPANY SNAPSHOT
    • 18.7.2 PRODUCT PORTFOLIO
    • 18.7.3 RECENT DEVELOPMENT
  • 18.8 BIOGENIQ INC.
    • 18.8.1 COMPANY SNAPSHOT
    • 18.8.2 PRODUCT PORTFOLIO
    • 18.8.3 RECENT DEVELOPMENT
  • 18.9 COLOR
    • 18.9.1 COMPANY SNAPSHOT
    • 18.9.2 PRODUCT PORTFOLIO
    • 18.9.3 RECENT DEVELOPMENTS
  • 18.10 CNSDOSE
    • 18.10.1 COMPANY SNAPSHOT
    • 18.10.2 PRODUCT PORTFOLIO
    • 18.10.3 RECENT DEVELOPMENT
  • 18.11 CORIELL LIFE SCIENCES
    • 18.11.1 COMPANY SNAPSHOT
    • 18.11.2 PRODUCT PORTFOLIO
    • 18.11.3 RECENT DEVELOPMENTS
  • 18.12 DYNAMIC DNA LABORATORIES
    • 18.12.1 COMPANY SNAPSHOT
    • 18.12.2 PRODUCT PORTFOLIO
    • 18.12.3 RECENT DEVELOPMENTS
  • 18.13 GENELEX
    • 18.13.1 COMPANY SNAPSHOT
    • 18.13.2 PRODUCT PORTFOLIO
    • 18.13.3 RECENT DEVELOPMENT
  • 18.14 GENOMIND, INC.
    • 18.14.1 COMPANY SNAPSHOT
    • 18.14.2 PRODUCT PORTFOLIO
    • 18.14.3 RECENT DEVELOPMENTS
  • 18.15 GENXYS
    • 18.15.1 COMPANY SNAPSHOT
    • 18.15.2 PRODUCT PORTFOLIO
    • 18.15.3 RECENT DEVELOPMENTS
  • 18.16 HEALTHSPEK
    • 18.16.1 COMPANY SNAPSHOT
    • 18.16.2 PRODUCT PORTFOLIO
    • 18.16.3 RECENT DEVELOPMENT
  • 18.17 HUDSONALPHA HEALTH ALLIANCE (A DIVISION OF HUDSONALPHA)
    • 18.17.1 COMPANY SNAPSHOT
    • 18.17.2 PRODUCT PORTFOLIO
    • 18.17.3 RECENT DEVELOPMENT
  • 18.18 LUMINEX CORPORATION
    • 18.18.1 COMPANY SNAPSHOT
    • 18.18.2 REVENUE ANALYSIS
    • 18.18.3 PRODUCT PORTFOLIO
    • 18.18.4 RECENT DEVELOPMENTS
  • 18.19 MILLENNIUM HEALTH
    • 18.19.1 COMPANY SNAPSHOT
    • 18.19.2 PRODUCT PORTFOLIO
    • 18.19.3 RECENT DEVELOPMENTS
  • 18.20 MYDNA LIFE AUSTRALIA PTY LTD.
    • 18.20.1 COMPANY SNAPSHOT
    • 18.20.2 PRODUCT PORTFOLIO
    • 18.20.3 RECENT DEVELOPMENT
  • 18.21 ONEOME
    • 18.21.1 COMPANY SNAPSHOT
    • 18.21.2 PRODUCT PORTFOLIO
    • 18.21.3 RECENT DEVELOPMENTS
  • 18.22 OMECARE
    • 18.22.1 COMPANY SNAPSHOT
    • 18.22.2 PRODUCT PORTFOLIO
    • 18.22.3 RECENT DEVELOPMENT
  • 18.23 PERKINELMER INC.
    • 18.23.1 COMPANY SNAPSHOT
    • 18.23.2 REVENUE ANALYSIS
    • 18.23.3 PRODUCT PORTFOLIO
    • 18.23.4 RECENT DEVELOPMENTS
  • 18.24 R-BIOPHARM AG
    • 18.24.1 COMPANY SNAPSHOT
    • 18.24.2 PRODUCT PORTFOLIO
    • 18.24.3 RECENT DEVELOPMENTS

19 QUESTIONNAIRE

20 RELATED REPORTS

LIST OF TABLES

  • TABLE 1 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, (2021-2028)(USD MILLION)
  • TABLE 2 NORTH AMERICA WHOLE GENOME SEQUENCING IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 3 NORTH AMERICA ARRAY-BASED TESTS IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 4 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, (2021-2028)(USD MILLION)
  • TABLE 5 NORTH AMERICA CYP2C19 IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 6 NORTH AMERICA CYP2C9 AND VKORC1 IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 7 NORTH AMERICA CYP2D6 IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 8 NORTH AMERICA HLA-B IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 9 NORTH AMERICA HTR2A/C IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 10 NORTH AMERICA HLA-A IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 11 NORTH AMERICA CYP3A4 IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 12 NORTH AMERICA SLC6A4 IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 13 NORTH AMERICA MTHFR IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 14 NORTH AMERICA COMT IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 15 NORTH AMERICA OTHERS IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 16 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, (2021-2028)(USD MILLION)
  • TABLE 17 NORTH AMERICA PRESCRIPTION DRUGS IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 18 NORTH AMERICA OVER-THE-COUNTER MEDICATIONS IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 19 NORTH AMERICA RECREATIONAL DRUGS IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 20 NORTH AMERICA VITAMINS/NUTRACEUTICALS IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 21 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE, (2021-2028)(USD MILLION)
  • TABLE 22 NORTH AMERICA SALIVA IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 23 NORTH AMERICA BLOOD IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 24 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, (2021-2028)(USD MILLION)
  • TABLE 25 NORTH AMERICA DRUG DEVELOPMENT IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 26 NORTH AMERICA CLINICAL PRACTICE IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 27 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, (2021-2028)(USD MILLION)
  • TABLE 28 NORTH AMERICA PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 29 NORTH AMERICA HEALTHCARE PROVIDERS IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 30 NORTH AMERICA RESEARCH CENTRES AND ACADEMIC INSTITUTES IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 31 NORTH AMERICA OTHERS IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 32 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, (2021-2028)(USD MILLION)
  • TABLE 33 NORTH AMERICA RETAIL PHARMACIES IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 34 NORTH AMERICA HOSPITAL PHARMACIES IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 35 NORTH AMERICA MAIL-ORDER PHARMACIES IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION))
  • TABLE 36 NORTH AMERICA DIRECT-TO-CUSTOMER SERVICES IN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 37 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 38 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 39 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)
  • TABLE 40 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
  • TABLE 41 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
  • TABLE 42 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 43 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 44 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 45 U.S. PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 46 U.S. PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)
  • TABLE 47 U.S. PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
  • TABLE 48 U.S. PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
  • TABLE 49 U.S. PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 50 U.S. PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 51 U.S. PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 52 CANADA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 53 CANADA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)
  • TABLE 54 CANADA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
  • TABLE 55 CANADA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
  • TABLE 56 CANADA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 57 CANADA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 58 CANADA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • TABLE 59 MEXICO PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 60 MEXICO PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, 2021-2028 (USD MILLION)
  • TABLE 61 MEXICO PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, 2021-2028 (USD MILLION)
  • TABLE 62 MEXICO PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE, 2021-2028 (USD MILLION)
  • TABLE 63 MEXICO PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • TABLE 64 MEXICO PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, 2021-2028 (USD MILLION)
  • TABLE 65 MEXICO PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

LIST OF FIGURES

  • FIGURE 1 NORTH AMERICA PHARMACOGENTIC TESTIG IN PSYCHIATRY/DEPRESSION MARKET: SEGMENTATION
  • FIGURE 2 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRIC/DEPRESSION MARKET: DATA TRIANGULATION
  • FIGURE 3 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRIC/DEPRESSION MARKET: DROC ANALYSIS
  • FIGURE 4 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRIC/DEPRESSION MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
  • FIGURE 5 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRIC/DEPRESSION MARKET: COMPANY RESEARCH ANALYSIS
  • FIGURE 6 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRIC/DEPRESSION MARKET: INTERVIEW DEMOGRAPHICS
  • FIGURE 7 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRIC/DEPRESSION MARKET: DBMR MARKET POSITION GRID
  • FIGURE 8 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: MARKET APPLICATION COVERAGE GRID
  • FIGURE 9 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: VENDOR SHARE ANALYSIS
  • FIGURE 10 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: SEGMENTATION
  • FIGURE 11 INITIATIVES TAKEN BY MANUFACTURERS IS EXPECTED TO DRIVE THE NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
  • FIGURE 12 WHOLE GENOME SEQUENCING SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET IN 2021 & 2028
  • FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET
  • FIGURE 14 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE, 2021-2028
  • FIGURE 15 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE, 2021-2028 (USD MILLION)
  • FIGURE 16 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE, CAGR (2021-2028)
  • FIGURE 17 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE, LIFELINE CURVE
  • FIGURE 18 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY GENES, 2021-2028
  • FIGURE 19 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY GENES, 2021-2028 (USD MILLION)
  • FIGURE 20 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY GENES, CAGR (2021-2028)
  • FIGURE 21 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY GENES, LIFELINE CURVE
  • FIGURE 22 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DRUG TYPE, 2021-2028
  • FIGURE 23 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DRUG TYPE, 2021-2028 (USD MILLION)
  • FIGURE 24 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DRUG TYPE, CAGR (2021-2028)
  • FIGURE 25 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DRUG TYPE, LIFELINE CURVE
  • FIGURE 26 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY SAMPLE TYPE, 2021-2028
  • FIGURE 27 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY SAMPLE TYPE, 2021-2028 (USD MILLION)
  • FIGURE 28 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DRUG TYPE, CAGR (2021-2028)
  • FIGURE 29 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY SAMPLE TYPE, LIFELINE CURVE
  • FIGURE 30 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY APPLICATION, 2021-2028
  • FIGURE 31 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY APPLICATION, 2021-2028 (USD MILLION)
  • FIGURE 32 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY APPLICATION, CAGR (2021-2028)
  • FIGURE 33 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY APPLICATION, LIFELINE CURVE
  • FIGURE 34 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY END USER, 2021-2028
  • FIGURE 35 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY END USER, 2021-2028 (USD MILLION)
  • FIGURE 36 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY END USER, CAGR (2021-2028)
  • FIGURE 37 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY END USER, LIFELINE CURVE
  • FIGURE 38 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DISTRIBUTION CHANNEL, 2021-2028
  • FIGURE 39 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
  • FIGURE 40 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
  • FIGURE 41 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
  • FIGURE 42 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: SNAPSHOT (2020)
  • FIGURE 43 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020)
  • FIGURE 44 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2021 & 2028)
  • FIGURE 45 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020 & 2028)
  • FIGURE 46 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE (2021-2028)
  • FIGURE 47 NORTH AMERICA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: COMPANY SHARE 2020 (%)
Back to Top